Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

18 Dec 2014

Abstract excerpt

Patients with congenital haemophilia with inhibitors or acquired haemophilia are at risk of bleeding complications during surgery. In these patients, replacement therapy for the missing coagulation factor is ineffective, and a bypassing agent such as recombinant activated factor VII (rFVIIa) is required to manage bleeding. To evaluate the safety and haemostatic efficacy of rFVIIa treatment in Japanese patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25521821
DOI: 10.1111/hae.12611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in JapanPMID 25521821Read ↗

Optimizing Surgical Approaches for Patients with Inherited Factor VII Deficiency.Semantic proximity Read ↗

Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan.Semantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.Semantic proximity Read ↗

Surgery with emicizumab prophylaxis for two pediatric patients with severe haemophilia A with inhibitorsSemantic proximity Read ↗

Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidenceSemantic proximity Read ↗

Recombinant porcine sequence factor VIII (rp FVIII ) for acquired haemophilia A: practical clinical experience of its use in seven patientsSemantic proximity Read ↗

Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?*Semantic proximity Read ↗

Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery.Semantic proximity Read ↗

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.Semantic proximity Read ↗

Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders.Semantic proximity Read ↗

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.